Burning Rock Biotech, Dizal announce NMPA approval for sunvozertinib CDx

Burning Rock Biotech and Dizal jointly announced that the companion diagnostic, or CDx, for EGFR exon 20 insertion mutation, or exon20ins, for sunvozertinib, developed through their collaboration, has been approved by the National Medical Products Administration, or NMPA, of China. This marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China. The approval of this CDx test is the result of the simultaneous development of Burning Rock’s independently developed LungCure CDx and Dizal’s innovative EGFR exon20ins targeted therapy – sunvozertinib, providing an innovative precision treatment solution for non-small cell lung cancer patients with EGFR exon20ins.